It appears that Mesoblast has also completed the submission of its rolling BLA to the FDA for approval of its product candidate for acute gvhd.
From today's anouncement:
About MesoblastSee below for comparison:
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-the- shelf) cellular medicines. The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Two products have been commercialized in Japan and Europe by its licensees, and it has established commercial partnerships in Europe and China for certain Phase 3 assets. In the United States, Mesoblast completed submission of a rolling Biologics License Application to the FDA to seek approval of its product candidate for acute graft versus host disease following a successful Phase 3 trial and is completing Phase 3 trials for its advanced heart failure and chronic low back pain product candidates.
From previous announcement dated 27/11/2019 (Mesoblast Chairman Message to 2019 AGM)
About Mesoblast
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-theshelf) cellular medicines. The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Two products have been commercialized in Japan and Europe by its licensees, and it has established commercial partnerships in Europe and China for certain Phase 3 assets. In the United States, Mesoblast has initiated submission of a rolling Biologics License Application to the FDA to seek approval of its product candidate for acute graft versus host disease following a successful Phase 3 trial, and is completing Phase 3 trials for its advanced heart failure and chronic low back pain product candidates. Mesoblast’s proprietary manufacturing process yields industrial-scale, frozen, off-the
You can verify the abvove info yourself by reading these two announcements.
- Forums
- ASX - By Stock
- MSB
- Submission of rolling BLA to the FDA for acute GVHD completed
Submission of rolling BLA to the FDA for acute GVHD completed
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.21 |
Change
-0.093(7.09%) |
Mkt cap ! $1.364B |
Open | High | Low | Value | Volume |
$1.27 | $1.30 | $1.17 | $9.557M | 7.741M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 72125 | $1.21 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.22 | 34729 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 72125 | 1.210 |
9 | 33365 | 1.205 |
15 | 93080 | 1.200 |
10 | 124967 | 1.195 |
6 | 51119 | 1.190 |
Price($) | Vol. | No. |
---|---|---|
1.215 | 40229 | 7 |
1.220 | 71346 | 12 |
1.225 | 109247 | 11 |
1.230 | 79673 | 10 |
1.235 | 41246 | 7 |
Last trade - 11.07am 24/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online